Annalisa Lattanzi

List of Publications by Year in descending order

16 papers	691 citations	932766 10 h-index	1125271 13 g-index
16 all docs	16 docs citations	16 times ranked	1071 citing authors

#	Article	IF	Citations
1	Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human Î²-globin locus. Blood, 2018, 131, 1960-1973.	0.6	156
2	Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. Molecular Therapy, 2019, 27, 137-150.	3.7	97
3	Development of Î²-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Science Translational Medicine, 2021, 13, .	5.8	82
4	Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. Human Molecular Genetics, 2010, 19, 2208-2227.	1.4	77
5	Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy. Human Molecular Genetics, 2014, 23, 3250-3268.	1.4	56
6	Pervasive supply of therapeutic lysosomal enzymes in the <scp>CNS</scp> of normal and Krabbeâ€affected nonâ€human primates by intracerebral lentiviral gene therapy. EMBO Molecular Medicine, 2016, 8, 489-510.	3.3	50
7	Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System. Molecular Therapy - Nucleic Acids, 2017, 7, 11-19.	2.3	44
8	Specific Determination of Î²-Galactocerebrosidase Activity via Competitive Inhibition of Î²-Galactosidase. Clinical Chemistry, 2009, 55, 541-548.	1.5	43
9	Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16060.	1.8	41
10	Dynamic Activity of miR-125b and miR-93 during Murine Neural Stem Cell Differentiation In Vitro and in the Subventricular Zone Neurogenic Niche. PLoS ONE, 2013, 8, e67411.	1.1	30
11	Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency. Molecular Therapy - Methods and Clinical Development, 2021, 22, 237-248.	1.8	11
12	Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and Î²-Thalassemia. Blood, 2016, 128, 4708-4708.	0.6	2
13	Induction of Fetal Hemoglobin Synthesis By Crispr/Cas9-Mediated Disruption of the Î²-Globin Locus Architecture. Blood, 2016, 128, 321-321.	0.6	2
14	131. Targeted Genome Editing in Spinal Muscular Atrophy. Molecular Therapy, 2015, 23, S53-S54.	3.7	0
15	135. Optimization of Dual-gRNA Lentiviral Vectors for Targeted Genomic Deletions. Molecular Therapy, 2016, 24, S55.	3.7	0
16	559. Induction of Fetal Hemoglobin in Adult Erythroblasts by Genome Editing of the Beta-Globin Locus. Molecular Therapy, 2016, 24, S223-S224.	3.7	0